CytRx Current Ratio 2010-2022 | CYTR

CytRx current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
CytRx Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $0.01B $0.00B 1.99
2021-12-31 $0.01B $0.00B 2.22
2021-09-30 $0.02B $0.00B 5.94
2021-06-30 $0.01B $0.00B 3.53
2021-03-31 $0.01B $0.00B 3.77
2020-12-31 $0.01B $0.00B 4.12
2020-09-30 $0.02B $0.01B 3.13
2020-06-30 $0.02B $0.00B 6.59
2020-03-31 $0.02B $0.00B 7.37
2019-12-31 $0.02B $0.00B 8.39
2019-09-30 $0.02B $0.00B 6.36
2019-06-30 $0.02B $0.00B 10.73
2019-03-31 $0.02B $0.00B 9.09
2018-12-31 $0.02B $0.00B 8.78
2018-09-30 $0.03B $0.01B 3.06
2018-06-30 $0.04B $0.02B 2.30
2018-03-31 $0.04B $0.02B 1.92
2017-12-31 $0.05B $0.03B 1.56
2017-09-30 $0.05B $0.03B 1.71
2017-06-30 $0.06B $0.02B 2.44
2017-03-31 $0.05B $0.02B 2.46
2016-12-31 $0.06B $0.02B 3.11
2016-09-30 $0.06B $0.02B 3.06
2016-06-30 $0.06B $0.02B 3.81
2016-03-31 $0.07B $0.02B 3.86
2015-12-31 $0.06B $0.02B 2.80
2015-09-30 $0.07B $0.01B 5.59
2015-06-30 $0.06B $0.02B 2.96
2015-03-31 $0.07B $0.02B 3.24
2014-12-31 $0.08B $0.02B 4.68
2014-09-30 $0.10B $0.02B 5.14
2014-06-30 $0.11B $0.02B 4.67
2014-03-31 $0.11B $0.02B 6.81
2013-12-31 $0.04B $0.03B 1.33
2013-09-30 $0.02B $0.01B 1.80
2013-06-30 $0.03B $0.01B 3.30
2013-03-31 $0.03B $0.01B 3.12
2012-12-31 $0.04B $0.01B 3.94
2012-09-30 $0.02B $0.02B 1.15
2012-06-30 $0.03B $0.03B 1.04
2012-03-31 $0.03B $0.02B 1.73
2011-12-31 $0.04B $0.01B 2.74
2011-09-30 $0.04B $0.02B 2.71
2011-06-30 $0.03B $0.01B 4.18
2011-03-31 $0.03B $0.01B 3.78
2010-12-31 $0.04B $0.01B 5.87
2010-09-30 $0.04B $0.01B 5.93
2010-06-30 $0.04B $0.01B 7.63
2010-03-31 $0.04B $0.01B 4.76
2009-12-31 $0.04B $0.01B 4.99
2009-09-30 $0.04B $0.01B 5.17
2009-06-30 $0.02B $0.00B 5.81
2009-03-31 $0.02B $0.01B 3.96
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.006B $0.000B
CYTRX CORP. is engaged in the development and commercialization of pharmaceutical related products and services including human therapeutics focused on high-value critical- care therapies.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00